Investment Thesis
Aptose Biosciences is in critical financial distress with negative stockholders' equity of -$19.4M, indicating liabilities exceed assets. The company generates zero revenue while burning $16.1M in annual operating cash flow, with only $613K in cash reserves and a current ratio of 0.53x indicating severe liquidity crisis. Continued operations appear unsustainable without significant capital infusion or strategic intervention.
Strengths
- Minimal capital expenditure ($5K) suggests focus on R&D rather than infrastructure spending
- Biotech sector positioning offers potential for transformative breakthroughs if pipeline succeeds
- No reportable long-term debt structure (though liabilities of $25.8M represent immediate concern)
Risks
- Negative stockholders' equity of -$19.4M indicates technical insolvency and high bankruptcy risk
- Zero revenue generation with -$16.1M operating cash burn rate unsustainable with only $613K cash
- Current ratio of 0.53x and quick ratio of 0.53x signal acute liquidity crisis and inability to meet short-term obligations
- Deteriorating financial position despite 50.3% improvement in net loss suggests accounting adjustments rather than operational improvement
- No insider purchases in last 90 days suggests lack of management confidence
Key Metrics to Watch
- Cash balance trend and runway (critical given monthly burn rate)
- Ability to raise capital or secure financing to extend runway
- Clinical trial progress and regulatory milestones for pipeline assets
- Liability restructuring or debt reduction initiatives
- Operating cash burn rate stabilization
Financial Metrics
Revenue
0.0
Net Income
-17.7M
EPS (Diluted)
$-7.34
Free Cash Flow
-16.2M
Total Assets
6.3M
Cash
613.0K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-279.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.53x
Quick Ratio
0.53x
Debt/Equity
N/A
Debt/Assets
406.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T01:36:11.144024 |
Data as of: 2025-09-30 |
Powered by Claude AI